<?xml version="1.0" encoding="UTF-8"?>
<p>Therefore, the FML-saponin vaccine showed high efficacy against severe end-points such as severe disease and deaths due to ZVL and provided long-lasting preventive protection that was probably also responsible for the detected decrease in human VL cases in that area: from 15 cases before the beginning of the vaccination assay to zero before its end (
 <xref rid="B101" ref-type="bibr">101</xref>). Due to these results, the FML-vaccine was considered the only effective canine vaccine against leishmaniasis, in the Second–Generation Vaccines against Leishmania Meeting held by the WHO-TDR program in Mexico in 2001 (
 <xref rid="B84" ref-type="bibr">84</xref>). The FML-saponin vaccine increases the IgG2 type response compared to IgG1 antibodies, against FML in vaccinated dogs (
 <xref rid="B102" ref-type="bibr">102</xref>). This kind of response is observed in dogs vaccinated against ZVL or in naturally protected dogs (
 <xref rid="B103" ref-type="bibr">103</xref>–
 <xref rid="B107" ref-type="bibr">107</xref>). The FML-saponin vaccine, with an increased dose of the adjuvant, was also shown to be immunotherapeutic in dogs vaccinated while infected but asymptomatic (
 <xref rid="B108" ref-type="bibr">108</xref>).
</p>
